{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:43:45Z","timestamp":1785775425547,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-025-01882-8","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T04:15:31Z","timestamp":1740543331000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Fatemeh","family":"Shojaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azam","family":"Erfanifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeid","family":"Kalbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahriar","family":"Nikpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latif","family":"Gachkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"issue":"6","key":"1882_CR1","doi-asserted-by":"publisher","first-page":"846","DOI":"10.4254\/wjh.v7.i6.846","volume":"7","author":"SM Abd El-Kader","year":"2015","unstructured":"Abd El-Kader SM, El-Den Ashmawy EMS. Non-alcoholic fatty liver disease: the diagnosis and management. World J Hepatol. 2015;7(6):846.","journal-title":"World J Hepatol"},{"issue":"38","key":"1882_CR2","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.2174\/1381612825666190117102111","volume":"24","author":"M Papatheodoridi","year":"2018","unstructured":"Papatheodoridi M, Cholongitas E. Diagnosis of non-alcoholic fatty liver disease (NAFLD): current concepts. Curr Pharm Design. 2018;24(38):4574\u201386.","journal-title":"Curr Pharm Design"},{"issue":"6","key":"1882_CR3","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.bpg.2004.06.021","volume":"18","author":"H Cortez-Pinto","year":"2004","unstructured":"Cortez-Pinto H, Camilo ME. Non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis (NAFLD\/NASH): diagnosis and clinical course. Best Pract Res Clin Gastroenterol. 2004;18(6):1089\u2013104.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"9","key":"1882_CR4","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.3390\/ijms22094495","volume":"22","author":"H Kim","year":"2021","unstructured":"Kim H, Lee DS, An TH, Park H-J, Kim WK, Bae K-H, Oh K-J. Metabolic spectrum of liver failure in type 2 diabetes and obesity: from NAFLD to NASH to HCC. Int J Mol Sci. 2021;22(9):4495.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1882_CR5","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","volume":"70","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. 2021;70(5):962\u20139.","journal-title":"Gut"},{"issue":"5","key":"1882_CR6","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3390\/jcm11051375","volume":"11","author":"M Kosmalski","year":"2022","unstructured":"Kosmalski M, Zi\u00f3\u0142kowska S, Czarny P, Szemraj J, Pietras T. The coexistence of nonalcoholic fatty liver disease and type 2 diabetes mellitus. J Clin Med. 2022;11(5):1375.","journal-title":"J Clin Med"},{"issue":"4","key":"1882_CR7","doi-asserted-by":"publisher","first-page":"6184","DOI":"10.3390\/ijms15046184","volume":"15","author":"UJ Jung","year":"2014","unstructured":"Jung UJ, Choi M-S. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15(4):6184\u2013223.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1882_CR8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/17474124.2019.1649981","volume":"13","author":"M Arrese","year":"2019","unstructured":"Arrese M, Barrera F, Triantafilo N, Arab JP. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. Expert Rev Gastroenterol Hepatol. 2019;13(9):849\u201366.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"10","key":"1882_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/0115733998271026231127051545","volume":"20","author":"J Yadav","year":"2024","unstructured":"Yadav J, Ahsan F, Panda P, Mahmood T, Ansari VA, Shamim A. Empagliflozin-A Sodium glucose co-transporter-2 inhibitor: overview of its Chemistry, Pharmacology, and Toxicology. Curr Diabetes Rev. 2024;20(10):30\u201352.","journal-title":"Curr Diabetes Rev"},{"key":"1882_CR10","doi-asserted-by":"crossref","unstructured":"Bonora BM, Avogaro A, Fadini GP. Extraglycemic effects of SGLT2 inhibitors: a review of the evidence. Diabetes Metab Syndr Obes. 2020;13:161\u2013\u200974.","DOI":"10.2147\/DMSO.S233538"},{"key":"1882_CR11","doi-asserted-by":"publisher","first-page":"836455","DOI":"10.3389\/fendo.2022.836455","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Liu X, Zhang H, Wang X. Efficacy and safety of empagliflozin on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Front Endocrinol. 2022;13:836455.","journal-title":"Front Endocrinol"},{"issue":"6","key":"1882_CR12","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3390\/medicina59061136","volume":"59","author":"I-C Bica","year":"2023","unstructured":"Bica I-C, Stoica RA, Salmen T, Jane\u017e A, Vol\u010dan\u0161ek \u0160, Popovic D, et al. The effects of sodium-glucose cotransporter 2-inhibitors on steatosis and fibrosis in patients with non-alcoholic fatty liver disease or steatohepatitis and type 2 diabetes: a systematic review of randomized controlled trials. Medicina. 2023;59(6):1136.","journal-title":"Medicina"},{"issue":"3","key":"1882_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","volume":"45","author":"A Scheen","year":"2019","unstructured":"Scheen A. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications. Diabetes Metab. 2019;45(3):213\u201323.","journal-title":"Diabetes Metab"},{"key":"1882_CR14","doi-asserted-by":"publisher","first-page":"105319","DOI":"10.1016\/j.phrs.2020.105319","volume":"163","author":"M Simental-Mendia","year":"2021","unstructured":"Simental-Mendia M, Sanchez-Garcia A, Rodriguez-Ramirez M, Simental-Mendia LE. Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2021;163:105319.","journal-title":"Pharmacol Res"},{"key":"1882_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","volume":"12","author":"H Chehrehgosha","year":"2021","unstructured":"Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, Malek M, Reza Babaei M, Zamani F, et al. Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Therapy. 2021;12:843\u201361.","journal-title":"Diabetes Therapy"},{"issue":"8","key":"1882_CR16","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care. 2018;41(8):1801\u20138.","journal-title":"Diabetes Care"},{"key":"1882_CR17","doi-asserted-by":"crossref","unstructured":"Pokharel A, Sudhamshu K, Thapa P, Karki N, Shrestha R, Jaishi B, Paudel MS. The effect of empagliflozin on liver fat in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease. Cureus. 2021;13(7).","DOI":"10.7759\/cureus.16687"},{"issue":"2","key":"1882_CR18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2337\/dc19-0641","volume":"43","author":"S Kahl","year":"2020","unstructured":"Kahl S, Gancheva S, Stra\u00dfburger K, Herder C, Machann J, Katsuyama H, et al. Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care. 2020;43(2):298\u2013305.","journal-title":"Diabetes Care"},{"issue":"1","key":"1882_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s42000-018-0012-x","volume":"17","author":"E Chartampilas","year":"2018","unstructured":"Chartampilas E. Imaging of nonalcoholic fatty liver disease and its clinical utility. Hormones. 2018;17(1):69\u201381.","journal-title":"Hormones"},{"issue":"4","key":"1882_CR20","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/bimj.201800107","volume":"61","author":"V Rahlfs","year":"2019","unstructured":"Rahlfs V, Zimmermann H. Effect size measures and their benchmark values for quantifying benefit or risk of medicinal products. Biom J. 2019;61(4):973\u201382.","journal-title":"Biom J"},{"issue":"14","key":"1882_CR21","doi-asserted-by":"publisher","first-page":"6774","DOI":"10.1080\/03610926.2015.1134575","volume":"46","author":"J Olivier","year":"2017","unstructured":"Olivier J, May WL, Bell ML. Relative effect sizes for measures of risk. Commun statistics-theory Methods. 2017;46(14):6774\u201381.","journal-title":"Commun statistics-theory Methods"},{"issue":"408","key":"1882_CR22","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.2307\/2290095","volume":"84","author":"PA Lachenbruch","year":"1989","unstructured":"Lachenbruch PA. Statistical power analysis for the behavioral sciences. J Am Stat Assoc. 1989;84(408):1096\u20137.","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"1882_CR23","doi-asserted-by":"publisher","first-page":"e19070","DOI":"10.1371\/journal.pone.0019070","volume":"6","author":"TA Furukawa","year":"2011","unstructured":"Furukawa TA, Leucht S. How to obtain NNT from Cohen\u2019s d: comparison of two methods. PLoS ONE. 2011;6(4):e19070.","journal-title":"PLoS ONE"},{"issue":"6","key":"1882_CR24","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966\u201386.","journal-title":"Hepatology"},{"issue":"1","key":"1882_CR25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.22543\/2392-7674.1439","volume":"11","author":"MS Popoviciu","year":"2024","unstructured":"Popoviciu MS, Paduraru L, Rahman M, Supti FA, Stoica RA, Reurean Pintilei D, et al. The effects of SGLT2 inhibitors in patients with metabolic dysfunction-associated fatty liver disease; a narrative review. J Mind Med Sci. 2024;11(1):62\u201377.","journal-title":"J Mind Med Sci"},{"issue":"3","key":"1882_CR26","doi-asserted-by":"publisher","first-page":"e0151511","DOI":"10.1371\/journal.pone.0151511","volume":"11","author":"C Komiya","year":"2016","unstructured":"Komiya C, Tsuchiya K, Shiba K, Miyachi Y, Furuke S, Shimazu N, et al. Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLoS ONE. 2016;11(3):e0151511.","journal-title":"PLoS ONE"},{"key":"1882_CR27","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","volume":"61","author":"MC Thomas","year":"2018","unstructured":"Thomas MC, Cherney DZ. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018;61:2098\u2013107.","journal-title":"Diabetologia"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-01882-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-025-01882-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-01882-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T04:15:35Z","timestamp":1740543335000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-025-01882-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1882"],"URL":"https:\/\/doi.org\/10.1186\/s12902-025-01882-8","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"24 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received ethical approval from the Ethics Committee of Shahid Beheshti University of Medical Sciences, Tehran, Iran (Ethical code: IR.SBMU.MSP.REC.1400.287) and this study was conducted under the Declaration of Helsinki. After being informed of the research\u2019s benefits and risks, participants signed written consent. Registered retrospectively in the Iranian Registry of Clinical Trials (IRCT20210811052150N1) on April 16,2023 Access at .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}